Financial Comparison: Neumora Therapeutics (NASDAQ:NMRA) vs. Coeptis Therapeutics (NASDAQ:COEP)

Coeptis Therapeutics (NASDAQ:COEP) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings.

Valuation & Earnings

This table compares Coeptis Therapeutics and Neumora Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$80,000.00	151.04	-$21.27 million	($0.84)	-0.40
Neumora Therapeutics	N/A	N/A	-$235.93 million	N/A	N/A

Coeptis Therapeutics has higher revenue and earnings than Neumora Therapeutics.

Analyst Recommendations

This is a summary of recent recommendations for Coeptis Therapeutics and Neumora Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	0	0	1	0	3.00
Neumora Therapeutics	0	1	6	0	2.86

Coeptis Therapeutics currently has a consensus target price of $3.00, suggesting a potential upside of 796.06%. Neumora Therapeutics has a consensus target price of $22.57, suggesting a potential upside of 146.68%. Given Coeptis Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Coeptis Therapeutics is more favorable than Neumora Therapeutics.

Institutional and Insider Ownership

13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 21.5% of Coeptis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Coeptis Therapeutics and Neumora Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	N/A	-794.75%	-322.86%
Neumora Therapeutics	N/A	N/A	N/A

Summary

Coeptis Therapeutics beats Neumora Therapeutics on 5 of the 9 factors compared between the two stocks.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.

About Neumora Therapeutics

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.